Creatine and Mitochondrial Function: What the Research Shows

When most people think about creatine, they picture weightlifters and sprint athletes—muscles contracting hard, phosphocreatine stores depleted, ATP regenerated in seconds. That picture isn't wrong, but it is radically incomplete. A growing body of peer-reviewed research, including a landmark 2025 review in the EPMA Journal, now positions creatine as a key regulator of mitochondrial function—the cellular machinery responsible for virtually every sustained energy process in the human body. Understanding this deeper layer of creatine biology changes how we think about dosing, timing, and who benefits most.

The Mitochondria–Creatine Connection

Mitochondria are the organelles that convert oxygen and nutrients into ATP through oxidative phosphorylation. Every cell that works hard—muscle fibers, neurons, cardiac cells—depends on healthy mitochondria. But mitochondria don't work in isolation. They depend on a rapid, localized energy relay, and creatine is central to that relay.

Inside mitochondria, a specific isoform of creatine kinase called mitochondrial creatine kinase (MtCK) sits on the inner mitochondrial membrane. It catalyzes the transfer of a phosphate group from ATP (just synthesized by the electron transport chain) to creatine, producing phosphocreatine. That phosphocreatine then exits the mitochondria, travels to wherever ATP is being consumed, and donates its phosphate back—regenerating ATP on demand. This is called the phosphocreatine shuttle, and it is the cellular equivalent of a high-speed cargo network connecting your cell's power stations to every energy-hungry process within them.

What the 2025 EPMA Journal review makes clear is that this shuttle is not merely a passive relay. Creatine and MtCK actively stabilize the inner mitochondrial membrane, reduce proton leak, and maintain the membrane potential required for efficient ATP synthesis. Without adequate creatine, that system becomes less efficient—even if the mitochondria themselves are structurally intact.

Creatine and Mitochondrial Biogenesis: Growing New Power Plants

Beyond shuttling phosphate groups, creatine appears to influence how many mitochondria a cell produces in the first place. This process—mitochondrial biogenesis—is regulated in large part by a protein called PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), widely considered the "master regulator" of mitochondrial development.

A study published in PLOS ONE demonstrated that creatine supplementation in rodent muscle tissue was associated with upregulation of mitochondrial biogenesis markers, including PGC-1α and downstream proteins involved in mitochondrial membrane formation. More recently, 2026 mechanistic research has identified phosphocreatine's activation of the Nrf2/HO-1 and PGC-1α pathways as a route by which it reduces oxidative damage to mitochondrial membranes—a finding with significant implications for aging cells and metabolically stressed tissues.

In practical terms, this suggests that consistent creatine supplementation may help maintain—or modestly support—mitochondrial density in high-demand tissues. Exercise remains the gold-standard stimulus for biogenesis, but adequate creatine may help make the mitochondria you have work better and sustain that work longer.

The Creatine Kinase Isoforms: Tissue-Specific Roles

Most discussions of creatine kinase focus on the cytosolic isoform—the enzyme that regenerates ATP in the cytoplasm of muscle cells during explosive effort. But there are actually four major isoforms of creatine kinase, each tissue-specific and each playing a distinct role in cellular energy management:

• CK-MM — the dominant isoform in skeletal muscle; responsible for rapid ATP regeneration during short-duration exercise
• CK-MB — found in cardiac muscle; a well-established clinical biomarker for myocardial infarction
• CK-BB — the primary isoform in brain tissue; critical for neuronal energy buffering
• MtCK (sMtCK / uMtCK) — mitochondrial membrane-bound isoforms found in both muscle and non-muscle tissues; the key link between oxidative phosphorylation and the phosphocreatine shuttle

A 2024 study published in Science Translational Medicine found that decreased expression of mitochondrial creatine kinase 2 (MtCK2) significantly impaired skeletal muscle mitochondrial function in people with type 2 diabetes—and did so independently of insulin signaling. This is a striking finding: it means the creatine kinase system represents its own axis of metabolic control, parallel to and independent of the hormonal pathways most often implicated in metabolic disease.

For healthy individuals, the implication is clear: keeping creatine stores consistently topped up ensures that MtCK enzymes across all four tissue types have adequate substrate available—not only during exercise, but during the metabolic demands of everyday cellular maintenance.

Creatine, Oxidative Stress, and Redox Balance

Mitochondria are the primary site of reactive oxygen species (ROS) production in the cell. Under normal conditions, ROS production is modest and tightly regulated—antioxidant enzymes such as superoxide dismutase and glutathione peroxidase keep oxidative stress in check. Under heavy training loads, illness, caloric restriction, or aging, ROS generation can outpace antioxidant capacity, damaging mitochondrial membranes, proteins, and DNA.

The 2025 EPMA Journal review synthesizes evidence that creatine and the phosphocreatine system help maintain redox balance through three distinct mechanisms:

1. Membrane stabilization — MtCK activity reduces proton leak across the inner mitochondrial membrane, decreasing "idle" ROS generation that occurs when the membrane potential is disrupted.
2. Energy buffering — When ATP demand spikes acutely, phosphocreatine provides an immediate reserve, preventing the cell from entering an energy-depleted state where uncontrolled ROS production accelerates.
3. Pathway interactions — Emerging research points to phosphocreatine's activation of cytoprotective signaling cascades, including the Nrf2/HO-1 axis, which upregulates the cell's own antioxidant enzyme production.

It's worth noting what creatine is not doing here. It isn't scavenging free radicals directly the way vitamin C or astaxanthin do. Rather, it supports the structural and energetic conditions under which the cell's own antioxidant machinery functions optimally. This distinction matters practically: some antioxidant supplements taken around training can blunt training adaptations by neutralizing the ROS signals that trigger muscle protein synthesis. Creatine's redox support works through energetics and membrane stability—mechanisms that appear to be compatible with, rather than antagonistic to, exercise adaptations.

What This Means for Dosing and Populations

The mitochondrial research adds meaningful nuance to the familiar 3–5 g per day creatine maintenance recommendation. When the goal is peak anaerobic performance, that dose is well-supported by decades of literature. When the goal is maintaining mitochondrial creatine kinase substrate availability across multiple tissue types—skeletal muscle, brain, cardiac muscle—the same dose holds up, but the reasoning is different.

The 2025 EPMA review highlights 5 g of creatine monohydrate per day as a dose consistently associated with full muscle saturation in most healthy adults, and notes that MtCK function tracks closely with overall creatine store levels. Maintaining that level daily—rather than cycling off—is consistent with keeping MtCK substrate availability stable across tissues over time.

One population deserves particular attention here: vegetarians and vegans. Because dietary creatine comes exclusively from animal proteins (meat and fish provide roughly 1–2 g per day), plant-based eaters arrive at their baseline with significantly lower muscle creatine stores—roughly 20–30% below omnivores, according to a 2025 randomized controlled trial in Physiological Reports. Lower baseline stores mean the MtCK substrate pool starts in a suboptimal state—making supplementation not just a performance choice but a meaningful tool for supporting baseline mitochondrial function, even in non-athletes.

The Emerging Clinical Significance

The reframing of creatine as a mitochondrial support compound—rather than purely a performance supplement—is beginning to influence clinical research directions. The 2025 EPMA review proposes creatine profiling through biofluids, tissue sampling, and advanced imaging (such as proton magnetic resonance spectroscopy) as a potential early biomarker for bioenergetic dysfunction. Diseases characterized by mitochondrial impairment—including certain forms of heart failure, neurodegenerative conditions, and metabolic syndrome—show disrupted creatine kinase activity as an early feature, often before clinical symptoms emerge.

This doesn't mean creatine supplementation treats these conditions. What it means is that the creatine/phosphocreatine/MtCK system is now understood to be mechanistically central to mitochondrial health—and that this system requires an adequate substrate supply to function properly. For healthy individuals, keeping that system well-supplied through consistent supplementation is a strategy with a robust, decades-long safety record and a rapidly deepening mechanistic rationale.